$2.720
-0.318 (-11.69%)Zum Schluss
- High
- 2.975
- Open
- 2.960
- VWAP
- 2.73
- Vol
- 58.61K
- Mkt Cap
- —
- Low
- 2.500
- Amount
- 160.11K
- EV/EBITDA, TTM
- 0.00
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Bewertungskennzahlen
Event-Zeitleiste
News
9.508-11NewsfilterCOSCIENS Biopharma Reports Q2 2026 Financial Results
7.512-01GlobenewswireCOSCIENS Partners with Wuzhou for Exclusive Distribution of Macrilen® with €800,000 Initial Order
- 7.512-01Newsfilter
COSCIENS Partners with Wuzhou for Exclusive Distribution of Macrilen® with Initial Order of €800,000
- 9.005-30Newsfilter
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
5.005-30SeekingAlphaCOSCIENS Biopharma reconstitutes board
CSCI FAQ — answered by Alphio AI
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It operates in the Healthcare sector.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.